The drug’s success in a Phase 2 study in alpha-1 antitrypsin deficiency “validates” Sanofi’s 2024 acquisition of Inhibrx, ...

The negative readout led to a collapse in share price for Alector, which now plans to cut almost half of its workforce while ...

The Japanese pharma is licensing up to three next-generation cancer drugs from Innovent Biologics in a deal it believes to be ...

The San Francisco-area biotech has a therapy in mid-stage testing for secondary hemophagocytic lymphohistiocytosis, a rare ...

Analysts called the proposed purchase of Avadel Pharmaceuticals a “clear” strategic fit for Alkermes, handing it an already marketed product for excessive daytime sleepiness.

The prolific company creator is staking $50 million on AI drug discovery for cancer and immune diseases, launching a biotech ...

The Novo Foundation chair said the current board of the Wegovy maker, which is already dealing with layoffs and a CEO change, ...

Presented at the European Society for Medical Oncology, study results showed Datroway extended survival in breast cancer ...

Leaders and decision-makers facing the task of bringing new facilities online need construction partners who understand these ...

A closely watched trial in Chinese patients is raising hope that ivonescimab will outperform Keytruda in a large global study ...

Some on Wall Street weren’t too impressed with results from a pivotal trial that tested an Exelixis drug, zanzalintinib, in combination with Tecentriq.

Gov. Gavin Newsom signed an array of healthcare bills into law last week that crack down on pharmacy benefit managers and ...